Objective To study on the effects of Cinnamic aldehyde on leukemia cell line K562 by Caco -2 cells in vitro absorption model.Methods The effective components of cinnamon(0,50,100,200,400, 600,800,1000 μg· mL-1 ) were determined by Caco-2 cell model of Transwell, and the concentration was determined by HPLC.No cytotoxic concentration range of Cinnamic aldehyde acting on K562 cells for 72 h is detected by MTT assay.After 72 h incubation of Cinnamic aldehyde standard(50,75 μg· mL-1 ) and leukemia K562 cells, the cells surface antigens including CD235a, CD36, CD41, CD61, CD13, CD33 and CD14 were determined by Flow cytometry.Results The active ingredi-ent of cinnamon is extracted by transwell transport pool of Caco-2 cell model and no cytotoxic concentration is 200 μg · mL-1.The cinnamicaldehyde is the component which goes through the model by HPLC.The 24 h inhibition rates ( IRs ) of Cinnamic aldehyde on K562 cells are (25.29 ±0.97)%and (36.60 ±0.18)%at the concentrations of 50 and 75 μg· mL-1 , respectively;IRs for 48 h are ( 48.23 ±0.63 )% and ( 57.15 ±0.58 )%; IRs for 72 h are ( 58.23 ±0.63 )% and (57.15 ±0.58)%.Compared with the control group, the inhibitory activity is obvious(P<0.05).After incubation 72 h, the expressions of myeloid differentiation phenotypes including CD13, CD33, CD36 on K562 cells are (0.33 ±0.21)%, ( 32.89 ±0.19 )%, ( 7.73 ±0.57 )% and ( 0.72 ±0.43 )%, ( 38.80 ±0.03 )%, (10.90 ±0.82)%at the concentrations of 50 and 75 μg· mL-1 , respectively.Compared with the control group, the inhibition increased ( P <0.05 ).The phenotypic expressions of erythroid differentiation are ( 52.38 ±0.65 )%, (57.48 ±0.70)%.Compared with the control group, the inhibition increased( P<0.05).Megakaryocyte differentia-ted phenotype CD41, CD61 expression has no significant change ( P >0.05 ).Conclusion The Cinnamic aldehyde can go through the Caco-2 in vitro absorption model and enables the K562 cells to differentiate into myeloid and erythroid.

OBJECTIVETo explore the value of morphological examination, cytochemical staining combined with bone marrow biopsy in the differential diagnosis between myelodysplastic syndrome (MDS) with low blasts and hemolytic anemia (HA).

METHODSThe clinical data of 85 cases of myelodysplastic syndrome with low blasts (< 5%) and 61 patients with hemolytic anemia in Chinese PLA's Gerneral hospital from September 2009 to March 2015 were retrospectively analysed. The clinical characteristics, cytogenetic and molecular features, bone marrow cell count and morphology features, cytochemical staining results and bone marrow biopsy features of above-methioned patients were compared.

RESULTSThere was no significant difference (P > 0.05) in clinical data between MDS group and HA group. Megakaryocytic dysplasia-positive rate, and ring sideroblasts positive rate, and PAS positive rate were significantly higher in MDS group than those that in HA group (P < 0.05). Abnormal localization of immature precursors (ALIP) and megakaryocytic dysplasia positive rate in bone marrow biopsy were significantly higher in MDS group than those that in HA group (P < 0.05), 90.6% of MDS with low blasts patients were identifiable by combined detections.

CONCLUSIONCombining detection of morphology, cytochemistry staining and bone marrow biopsy has been confirmed to be more useful for differential diagnosis between MDS with low blasts and HA.

Anemia, Hemolytic ; complications ; diagnosis ; Biopsy ; Bone Marrow Cells ; cytology ; Diagnosis, Differential ; Erythroid Precursor Cells ; cytology ; Humans ; Megakaryocytes ; cytology ; Myelodysplastic Syndromes ; complications ; diagnosis ; Retrospective Studies ; Staining and Labeling